Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma

Taphoorn, Martin J.B.; Dirven, Linda; Kanner, Andrew A.; Lavy-Shahaf, Gitit; Weinberg, Uri; Taillibert, Sophie; Toms, Steven; Honnorat, Jérôme; Chen, Thomas C.; Šroubek, Jan; David, Carlos A.; Idbaïh, Ahmed; Easaw, Jacob C.; Kim, Chae Yong; Bruna, Jordi; Hottinger, Andreas F.; Kew, Yvonne; Roth, Patrick; Desai, Rajiv; Villanó, John L.; Kirson, Eilon D.; Ram, Zvi; Stupp, Roger

doi:10.1001/jamaoncol.2017.5082

Cited by 149 publications

(131 citation statements)

References 32 publications

Supporting

Mentioning

113

Contrasting

Order By: Relevance

“…The 5-year survival rate for patients in the TTFields plus TMZ group was 13% (vs. 5% for TMZ alone; P < 0.001), and the 2-year survival rate was 43% (vs. 31% for TMZ alone; P < 0.001) (4). Healthrelated quality of life was not compromised by the addition of TTFields (5).…”

Section: Introductionmentioning

confidence: 97%

Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 97%

Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mild to moderate scalp toxicity underneath the transducer arrays was seen in 52% of patients who received TTFields and temozolomide compared to none in the control cohort. Systemic toxicities and health-related quality-of-life measures were comparable between the two groups [2,17].…”

Section: Clinical Outcome From Ttfields Treatmentmentioning

confidence: 87%

Insights from Computer Modeling: Analysis of Physical Characteristics of Glioblastoma in Patients Treated with Tumor-Treating Fields

Lok

San

Wong

2019

Brain and Human Body Modeling

View full text Add to dashboard Cite

Tumor-treating fields (TTFields) are intermediate frequency electric fields at 200 kHz (kHz or 10 3 Hz) that have anti-tumor activity. In a pivotal phase III clinical trial for newly diagnosed glioblastoma patients, the addition of TTFields to maintenance temozolomide, which was administered after initial radiotherapy and concurrent daily temozolomide, was found to improve both progression-free survival and overall survival when compared to those who only received maintenance temozolomide [1, 2]. This positive trial result led the US FDA to approve the use of TTFields for these patients and the incorporation of this therapy into the National Comprehensive Cancer Network (NCCN) guidelines for malignant gliomas [3].

show abstract

“…However, after a median follow-up of 40 months, a significant median survival benefit of 4.9 months was evident (20.9 vs. 16.0 months) [27]. The health-related quality of life was equal in both arms of the trial [28]. Secondly, the results from the German CeTeG-Trial have been reported at the SNO conference in 2017.…”

Section: Glioblastomamentioning

confidence: 98%

The algorithms of adjuvant therapy in gliomas and their effect on survival

Straube¹,

Schmidt‐Graf²,

Wiestler³

et al. 2019

J Neurosurg Sci

View full text Add to dashboard Cite

The treatment of gliomas became more sophisticated during the last decades. As by now, adjuvant treatment after maximum safe resection is considered an important and effective treatment strategy in most gliomas, yet the decision is based on several factors. This review summarizes the available evidence for the current adjuvant treatment algorithms with a focus on the impact on the survival of glioma patients. The review is based on the current guidelines, but it also includes new insights which have not yet been included into the official guidelines.

show abstract

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma

Abstract: clinicaltrials.gov Identifier: NCT00916409.

Cited by 149 publications

References 32 publications

Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study

Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study

Insights from Computer Modeling: Analysis of Physical Characteristics of Glioblastoma in Patients Treated with Tumor-Treating Fields

The algorithms of adjuvant therapy in gliomas and their effect on survival

Contact Info

Product

Resources

About